Wavelength Pharmaceuticals, a leading developer and manufacturer of active pharmaceutical ingredients (APIs), announces the acquisition of a majority stake in Vanamali Organics Pvt. Ltd. of Telangana, India.
Vanamali is an experienced manufacturer of pharmaceutical key starting materials and advanced drug intermediates, with significant R&D capabilities. The acquisition allows Wavelength to further strengthen its long-standing drug substance manufacturing footprint and global supply chain, as well as its API CDMO business.
“Our success in building a world-class operation supplying the highest quality APIs reflects our close alignment with the needs of our customers,” said Iftach Seri, CEO of Wavelength Pharmaceuticals. “These include planning for an increasingly unpredictable world, where supply chain assurance and control of regulatory starting materials further back in the process have become a key strategic concern. Wavelength’s customers benefit from our three decades-long investment in creating the most robust supply chain in the industry.”
Seri continued, “The acquisition of Vanamali Organics represents the next stage of this investment strategy. We are impressed with Vanamali’s professionalism, commitment to quality and focus on sustainable growth. We are delighted to add their talented team and advanced development and manufacturing capabilities to Wavelength, and we expect they will be important contributors to our global supply chain network and our rapidly growing custom development and manufacturing services business.”
Vanamali Organics provides high quality customised process development and manufacturing services using advanced technologies and a quality-by-design approach to deliver eco-efficient regulatory compliant chemistry. Its researchers are skilled in managing process development, optimisation and scale-up, and the company’s modern manufacturing facilities can deliver small research quantities up to multi-ton commercial-scale production runs.
Dr Sreenivasan, Managing Director of Vanamali Organics, commented, “As scientists who have spent the past decade building a science- and quality-focused research and manufacturing business, we welcome the opportunity to join forces with Wavelength. There is a true alignment of values and perspectives between our two organisations, and we are excited by the tremendous potential for expansion and growth this combination provides.”
